117 results about "Carbapenem" patented technology

The invention discloses an antibacterial peptide based on D-type amino acid and application of the antibacterial peptide, and the antibacterial peptide is characterized in that the amino acid sequence is w-r-r-w-r-r-w-w-r-k-r (dTrp-dArg-dArg-dTrp-dArg-dArg-dTrp-dTrp-dArg-dLys-dArg). The antibacterial peptide can be synthesized through an Fmoc solid-phase chemical method, the synthesis difficulty is low, and the in-vivo antibacterial activity is good. The antibacterial peptide especially has broad-spectrum killing activity on carbapenem-resistant pseudomonas aeruginosa, pseudomonas aeruginosa, klebsiella pneumoniae, escherichia coli, methicillin-resistant staphylococcus aureus and staphylococcus aureus, is low in hemolytic toxicity, can reach half or more of cell survival rate under medium and low concentration, almost has no toxic effect on cells, and can be used for preparing the antibacterial peptide with a broad-spectrum killing activity on carbapenem-resistant pseudomonas aeruginosa, klebsiella pneumoniae, escherichia coli, methicillin-resistant staphylococcus aureus and staphylococcus aureus. The stability is good, the operability is high, and the cost is low.

The invention relates to the technical field of high-throughput targeted sequencing, in particular to a primer group for detecting important drug-resistant genes and virulence genes of multi-drug-resistant pathogenic bacteria and application of the primer group. Specifically, the kit comprises detection primers for multiple drug-resistant bacteria such as third-generation cephalosporin drug-resistant enterobacteriaceae bacteria, carbapenem drug-resistant enterobacteriaceae bacteria, carbapenem drug-resistant acinetobacter baumannii, rifampicin drug-resistant mycobacterium tuberculosis and the like. The method has the technical advantages of rapidness, high efficiency, strong targeting property, strong specificity and the like, is suitable for epidemic and difference analysis of various important drug-resistant genes and virulence genes carried by metagenome samples of various environments or disease materials and the like, evaluates the risk of related environments on the basis, and can further guide prevention and clinical treatment medication.

The invention discloses a carbapenem drug resistance gene detection reagent or kit, the detection reagent comprises a PCR detection liquid, the PCR detection liquid comprises upstream and downstream primer sequences and probe sequences of target genes, and the target genes are KPC, OXA-23, NDM, VIM and IMP. The invention also discloses application of the reagent or the kit. The reagent / kit provided by the invention has simple components, only comprises a PCR detection liquid and negative and positive quality control, can obtain detection results of five major carbapenem drug resistance genes, namely KPC, OXA-23, NDM, VIM and IMP, within about 50 minutes only once, and is simple and convenient to operate, low in detection cost, short in detection time and high in sensitivity. In addition, the lowest detectable concentration of detection of carbapenem drug resistance genes KPC, OXA-23, NDM, VIM and IMP is 10 copy / mL, and the sensitivity is high.

The invention discloses a deoxyribozyme probe for identifying carbapenem-resistant klebsiella pneumoniae and application of the deoxyribozyme probe, and belongs to the technical field of deoxyribozyme probes. The method comprises the following steps: firstly, mixing a phosphorylated library chain, a substrate chain and a connecting chain, then, carrying out covalent linkage to construct a DNA library, firstly, carrying out reverse screening, separating and purifying a DNA band of an uncut substrate RNA site, constructing a chain-shaped DNA library by using the obtained DNA band, carrying out forward screening, separating and purifying the DNA band of the cut substrate RNA site, carrying out PCR (Polymerase Chain Reaction) amplification, and recovering a positive-sense chain, so as to obtain the DNA library. The deoxyribozyme probe is obtained by performing repeated screening and enriching, and the probe can recognize carbapenem-resistant klebsiella pneumoniae with high specificity and has the potential of exerting advantages in the aspect of biosensing application.

The invention discloses an application of an antibacterial peptide and an application of the antibacterial peptide in preparation of antibacterial drugs for treating carbapenem-resistant pseudomonas aeruginosa, klebsiella pneumoniae (ATCC700603), escherichia coli (ATCC25922), staphylococcus aureus and methicillin-resistant staphylococcus aureus, the antibacterial peptide is characterized in that the sequence is w-r-r-w-k-r-w-w-r-r, and the sequence is shown in the description. All amino acids are D-type amino acids; the antibacterial peptide can be used as an antibacterial substance in wash supplies, food preservative additives, medical consumable antibacterial agents and cosmetics, can be synthesized through an Fmoc solid-phase chemical method, and is low in synthesis difficulty and good in in-vivo antibacterial activity. Particularly, the antibacterial peptide has broad-spectrum killing activity against carbapenem pseudomonas aeruginosa, klebsiella pneumoniae (ATCC700603), escherichia coli (ATCC25922), staphylococcus aureus and methicillin-resistant staphylococcus aureus, the cell survival rate of the antibacterial peptide within the range of medium and low concentration (2 mu g / mL-32 mu g / mL) reaches half or more, the toxicity is small, the toxicity is almost avoided, the operability is high, and the antibacterial peptide can be widely applied to the field of medical application. The cost is low.

The invention designs a carbapenem drug-resistant gene nucleic acid fluorescent PCR method detection kit and application thereof, the kit uses Taqman fluorescent probe multiple amplification technology to detect carbapenem drug-resistant genes, the kit comprises a nucleic acid reaction liquid Mix1 and a nucleic acid reaction liquid Mix2, the nucleic acid reaction liquid Mix1 is used for detecting drug-resistant genes IMP, NDM and OXA48, the nucleic acid reaction liquid Mix2 is used for detecting drug-resistant genes IMP, NDM and OXA48, and the nucleic acid reaction liquid Mix2 is used for detecting drug-resistant genes IMP, NDM and OXA48. The nucleic acid reaction liquid Mix2 is used for detecting drug resistance genes VIM, KPC and OXA23. The method is high in detection specificity, and the detection result is visual and easy to interpret. Clinical doctors are assisted to judge respiratory tract pathogen infection more comprehensively and more accurately. The kit covers six carbapenem drug resistance genes, is more comprehensive and accurate in detection, and is high in specificity and sensitivity. Meanwhile, multiple sample types can be detected, a sputum sample, an excrement sample and a rectum swab sample are detected through paramagnetic particle extraction, and pure bacterial colonies are directly detected without extraction.

The invention relates to an antibacterial peptide and application thereof. The amino acid sequence of the antibacterial peptide is as shown in SEQ ID No. 1. The antibacterial peptide has excellent broad-spectrum antibacterial activity, for example, the antibacterial peptide has antibacterial activity on bacteria of the genus Staphylococcus (Staphylococcus), the genus Acinetobacter (Acinetobacter) and the genus Bacillus (Bacillus). Under the background that the global bacterial drug resistance problem is increasingly severe and traditional antibiotics gradually lose efficacy on multi-drug-resistant bacteria, a new treatment means is provided for treating bacteria such as methicillin-resistant staphylococcus aureus, carbapenem-resistant acinetobacter baumannii and bacillus subtilis which bring huge threats to public health. And a new possibility is provided for solving the problem that no medicine can be used clinically.

The present invention relates to the pharmaceutical field, and provides a boric acid β-lactamase inhibitor or a use thereof. The boric acid β-lactamase inhibitor is a compound shown in formula (I), or an optical isomer or a pharmaceutically acceptable salt thereof: formula (I). The ultra-broad-spectrum boric acid β-lactamase inhibitor of the present invention has an inhibition effect on A, B, C, and D enzymes, and carbapenem drug-resistant bacteria such as Klebsiella pneumoniae, Escherichia coli, Enterobacter cloacae, Acinetobacter baumannii, and Pseudomonas aeruginosa.

The invention relates to an antibacterial peptide LK-KJT-B01 for gram-negative bacterium infection and a preparation method and application thereof.The antibacterial peptide LK-KJT-B01 can be extracted from bacillus laterosporus, has the advantages of being broad in spectrum, safe, free of toxicity and the like, has a very strong bactericidal effect on gram-negative bacterium infection, and can be used for preparing antibacterial peptide LK-KJT-B01 for gram-negative bacterium infection. Particularly, the sensitivity to carbapenem-resistant gram-negative bacteria is high, and the application prospect is very wide.

The present application relates to the field of biotechnology, in particular to a carbapenem-resistant escherichia coli phage and application thereof.A new escherichia coli phage vB_EOP_Se009 is isolated and purified, and the phage has good sterilization effect on carbapenem-resistant escherichia coli.The phage has strong tolerance to temperature and pH, is high in specificity and stability, can effectively solve the problem that carbapenem-resistant escherichia coli is resistant to multiple antibiotics, and provides an experimental basis for developing a preparation for preventing or treating carbapenem-resistant escherichia coli infection in clinic, and has great clinical application potential.

The present application belongs to the technical field of artificial intelligence assisted drug screening, and particularly relates to a method for screening active molecules against carbapenem-resistant enterobacteriaceae based on a LightGBM algorithm, a medium and an apparatus. The method constructs a LightGBM integrated learning framework, fuses ADME rules optimized for the outer membrane barrier characteristics of gram-negative bacteria and multi-target molecule docking verification, effectively solves the problem of data imbalance caused by the scarcity of active samples and the huge compound library, and significantly improves the hit rate of screening. The present application also provides a computer readable storage medium and an electronic device. By storing and executing the above program, the present application can quickly and standardizedly identify anti-CRE candidate molecules from a large number of compounds, greatly reducing the computing power cost and time cycle of new drug research and development. The present application is designed to overcome the bottleneck of gram-negative bacterial outer membrane permeation, and provides an efficient, accurate and intelligent screening tool for combating CRE super-bacterial infections.

The invention discloses an antibody as well as a preparation method and application thereof. The antibody has good binding activity with OXA-23 type carbapenem enzyme, and can reduce the carbapenem drug resistance level of the acinetobacter baumannii, so that the clinical use concentration of meropenem is reduced, and the treatment effect of meropenem on the acinetobacter baumannii is improved. In addition, the antibody disclosed by the invention can also inhibit OXA-23 protein secreted by bacteria, prevent the bacteria from hydrolyzing carbapenem antibiotics, increase the concentration of antibiotics in a medication part, and facilitate the removal of mixed infection with acinetobacter baumannii. The invention provides a new strategy for treating acinetobacter baumannii infection, and the application prospect is wide.

This invention relates to compounds of formula (I) and methods of treatment using the compounds. The compounds of the invention can be used in combination with antibacterial agents to treat bacterial infections. More specifically, the compounds of formula (I) can be used in combination with a class of antibacterial agents known as carbapenems. The novel compounds of the present invention are enzyme inhibitors and more particularly are metallo-β-lactamase inhibitors.

The invention provides a broad-spectrum bacteriophage capable of efficiently splitting carbapenem-resistant klebsiella pneumoniae and application of the broad-spectrum bacteriophage, and belongs to the technical field of biological medicines. The bacteriophage is named as P146043, the host spectrum of the bacteriophage is wide, the bacteriophage can be used for CRKP strains of four ST genotypes and eight KL capsule types, and the antibacterial effect is good; meanwhile, good acid and alkali resistance and temperature stability are achieved; and the bacteriophage has a synergistic antibacterial effect with other bacteriophages, so that the antibacterial time can be prolonged. The P146043 provides an effective method and a new prevention and treatment thought for prevention and treatment of CRKP infectious disease infection, and has a good application prospect.

This invention relates to the synthesis of compounds that can be used to treat bacterial infections in combination with other antibacterial agents, and more specifically in combination with a class of antibacterial agents known as carbapenems. The compounds resulting from the novel methods of the present invention are enzyme inhibitors and more particularly are metallo-β-lactamase inhibitors.

The present application relates to a kind of targeting bacterial UDP-N-acetylglucosamine enolpyruvate transaminase antibacterial compound and its application, the antibacterial compound is S-(4-chlorobenzyl) chloro isothiourea, its chemical structure is as shown in formula I: I;Or its pharmaceutically acceptable salt, stereoisomer, solvate, crystal form, isotopically labeled or prodrug.The antibacterial compound of the present application can effectively inhibit the growth of klebsiella pneumoniae, including carbapenem-resistant klebsiella pneumoniae and high virulence klebsiella pneumoniae;It also has good bacteriostatic effect on escherichia coli and pseudomonas aeruginosa;It is expected to be applied to the clinical treatment of infection caused by drug-resistant klebsiella pneumoniae and high virulence klebsiella pneumoniae and other pathogenic bacteria, and has important clinical significance and social benefits.

The application provides a drug delivery system for targeted treatment of inflammatory diseases and a preparation method and application thereof, and belongs to the technical field of biological drugs. The drug delivery system for targeted treatment of inflammatory diseases is M2 type macrophages phagocytizing drug-loaded nanoparticles, wherein the drug-loaded nanoparticles comprise a biodegradable high molecular material for coating drugs. The drug delivery system prepared by the application realizes lung targeted delivery through the natural inflammatory chemotaxis characteristics of M2 type macrophages, and in combination with the drug slow-release effect of the drug-loaded nanoparticles, the drug targeting and availability are significantly improved, so that the drug efficacy is improved, the biological safety is good, and a new effective means is provided for the clinical treatment of various inflammatory diseases including carbapenem-resistant Klebsiella pneumoniae (CRKP) pneumonia.

The present invention belongs to the field of microbiology and genetics technology, and in particular relates to a primer set and typing detection method and kit for detecting drug-resistant enzyme genes of bacterial strains, wherein the primer set is an amplification primer for β-lactamase-resistant genes and carbapenemase-resistant genes, wherein the β-lactamase-resistant genes include SHV, TEM, and CTX-M, and the carbapenemase-resistant genes include NDM, OXA-23, and KPC. PCR amplification is performed according to specific enzyme typing primers, and genomic DNA is extracted using a magnetic bead method to improve the efficiency and purity of DNA extraction, thereby optimizing the accuracy and efficiency of PCR. The specific enzyme typing results are confirmed by comparison with the NCBI database through agarose gel electrophoresis and subsequent sequencing analysis. The experimental process is simplified, the cost is reduced, and a scientific basis is provided for the screening and clinical use of new β-lactamase and carbapenemase inhibitors, with the advantages of high efficiency, accuracy, and cost-effectiveness.

The invention belongs to the technical field of gene detection, and particularly relates to a carbapenem drug resistance gene detection device and method.The carbapenem drug resistance gene detection device comprises a detector, a detection cavity is formed in the detector, a detection unit is arranged in the detection cavity, and the detection unit comprises a pneumatic control module, an optical detection module and a constant temperature module; a sealing cover for sealing the detection cavity is arranged on the top surface of the detector; a micro-fluidic chip is placed on a suction cup, the micro-fluidic chip is pressed to be adsorbed on the suction cup, then a sealing cover is closed, an electric telescopic rod moves downwards, a first spring pushes a connecting plate, the connecting plate drives the suction cup to move downwards, and the suction cup drives the chip to move downwards; when the micro-fluidic chip is placed in the groove, the bottom surface of the chip is in contact with the inner wall of the groove, and then the electric telescopic rod is closed, so that the micro-fluidic chip is fixed in the groove, and the micro-fluidic chips of different models and sizes can be fixed through the suction cup.

Compositions and methods are provided for treating bacterial infections, including those that are challenging to treat by conventional medications, such as hospital acquired bacterial pneumonia (HABP), ventilator associated bacterial pneumonia (VABP), and bacteremia, caused by carbapenem-resistant bacteria such as Acinetobacter baumannii and Pseudomonas aeruginosa.

The invention discloses a carbapenem drug resistance marker screening method and system based on a cross-species compressed Debrueine diagram and a medium. The method comprises the following steps: starting from whole genome sequencing data of gram-negative bacteria belonging to different species and carbapenem drug phenotypes of the gram-negative bacteria, constructing a compressed Debrueine graph based on cross-species joint data, and taking existence / deletion of nodes in the graph as unified genetic variation characteristics. Performing correlation analysis on the nodes and the drug resistance phenotypes by using a linear hybrid model to obtain a candidate node set related to the phenotypes; k-mer is extracted based on the candidate node sequence, and secondary statistical screening is completed in combination with chi-square test and mutual information; and finally determining a group of carbapenem drug-resistant genetic markers which can be applicable across species through a hierarchical feature selection strategy of random forest and XGBoost. Efficient dimension reduction of large-scale cross-species genome data, cross-species consistent variation representation and high-interpretability marker screening are achieved.

The invention belongs to the technical field of antibacterial drugs, and particularly relates to a benzo five-membered ring boric acid-3-methyl alkenyl acid compound as well as a preparation method and application thereof. The invention provides a benzo five-membered ring boric acid-3-methyl alkenyl acid compound as shown in a formula I. The benzo five-membered ring boric acid-3-methyl alkenyl acid compound has good and broad-spectrum inhibitory activity on metal beta-lactamase and / or serine beta-lactamase, has excellent antibacterial activity on various drug-resistant bacteria, and can reverse drug resistance of carbapenem drug-resistant bacteria. Therefore, the compound disclosed by the invention has a wide application prospect in preparation of inhibitors of metal beta-lactamase and / or serine beta-lactamase and drugs for reversing drug resistance of carbapenem drug-resistant bacteria. # imgabs0 #

This invention discloses a primer and probe set, kit, and method for detecting carbapenem resistance genes using point-of-care testing (POCT), belonging to the field of gene detection technology. The carbapenem resistance genes include: NDM, KPC, VIM, IMP, OXA, and GES; the primers and probes for the NDM gene include: SEQ ID NO.1, SEQ ID NO.2, and SEQ ID NO.3; the primers and probes for the KPC gene include: SEQ ID NO.4, SEQ ID NO.5, and SEQ ID NO.6; the primers and probes for the VIM gene include: SEQ ID NO.7, SEQ ID NO.8, and SEQ ID NO.9; the primers and probes for the IMP gene include: SEQ ID NO.10, SEQ ID NO.11, and SEQ ID NO.12; the primers and probes for the OXA gene include: SEQ ID NO.13, SEQ ID NO.14, SEQ ID NO.15, SEQ ID NO.16, SEQ ID NO.17, SEQ ID NO.18, SEQ ID NO.19, SEQ ID NO.20, and SEQ ID NO.21; and the primers and probes for the GES gene include: SEQ ID NO.22, SEQ ID NO.23, and SEQ ID NO.24. The primer and probe set, kit, and method of this invention can be used to detect carbapenem resistance genes NDM (75 subtypes), KPC (232 subtypes), VIM (90 subtypes), IMP (101 subtypes), GES (64 subtypes), and OXA-48, 23, 51, and 213 groups in a single detection tube. They have the advantages of short detection time, simple operation, wide coverage, good specificity, and prevention of contamination.

Provided herein are compositions, methods, systems and / or kits for detection of bacteria expressing enzymes that confer resistance to antimicrobial agents. Certain embodiments of the compositions, methods, systems and / or kits of the present disclosure are related to detection of carbapenemase-producing gram negative bacteria. Certain embodiments of the compositions, methods, systems and / or kits of the present disclosure are related to detection of Ambler Class A, B and / or D carbapenemase-producing enteric and non-fermenting gram negative rod bacteria.

The invention relates to the technical field of biological detection, in particular to a primer probe composition for detecting a KPC type carbapenem drug-resistant gene and application of the primer probe composition. In order to solve the technical problems of long detection time, missing detection of partial subtypes, existence of cross reaction, insufficient sensitivity and the like in KPC gene detection in the prior art, the invention discloses a primer probe composition for detecting KPC type carbapenem drug resistance genes, the primer probe composition comprises a primer pair, the primer pair comprises a forward primer and a reverse primer, and the forward primer and the reverse primer are used for detecting the KPC type carbapenem drug resistance genes. The nucleotide sequence of a forward primer is shown as SEQ ID NO: 1, and the nucleotide sequence of a reverse primer is shown as SEQ ID NO: 2; the nucleotide sequence of the probe is as shown in SEQ ID NO: 3. Meanwhile, a reaction system is optimized, a matched detection kit and a standardized detection process are constructed, detection can be completed within 45 minutes, and cross reaction with carbapenemase genes such as NDM, VIM, IMP and OXA does not exist.

This invention relates to the field of high-throughput targeted sequencing technology, and particularly to a primer set and its applications for detecting important drug resistance and virulence genes in multidrug-resistant pathogens. Specifically, it includes primers for detecting various drug-resistant bacteria, such as third-generation cephalosporin-resistant Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, carbapenem-resistant Acinetobacter baumannii, and rifampicin-resistant Mycobacterium tuberculosis. This invention offers advantages such as speed, efficiency, strong targeting, and high specificity. It is suitable for analyzing the prevalence and differential distribution of multiple important drug resistance and virulence genes carried in metagenomic samples from various environments or pathogenic materials, and can be used to assess the risk of related environments, further guiding preventative and clinical treatment medications.

The invention belongs to the technical field of bioengineering, and relates to a klebsiella pneumoniae type carbapenemase mutant KPC-171 as well as a coding gene and application thereof. The amino acid sequence of the mutant is as shown in SEQ ID NO. 1. The carbapenemase mutant KPC-171, which is newly found and can cause higher drug resistance of bacteria to ceftazidime / avibactam, and the coding nucleic acid of the carbapenemase mutant KPC-171 can be used for better preparing a carbapenemase activity inhibitor or enhancer.

The invention discloses an aromatic polyketone compound as well as a preparation method and application thereof. The compound GaB (3) has an effect of treating infection of multiple drug-resistant bacteria. The compound is obtained by being separated from a secondary metabolite of the symbiotic Streptomyces sp.QHH-9511 of licheniformis, and the compound 2, the compound 3, the compound 4 and the compound 5 are new compounds. According to the present invention, the research results show that the GaB can effectively sterilize a variety of drug-resistant bacteria (methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, carbapenem-resistant acinetobacter baumannii, multi-drug-resistant pseudomonas aeruginosa, multi-drug-resistant salmonella, and the like); in addition, the compound has the characteristics of broad-spectrum sterilization, biofilm formation inhibition and low-frequency drug resistance, and can be combined with other antibiotics to cope with super bacteria. Mechanism research shows that GaB is combined with glucosamine-6-phosphate synthetase (GlmS) to prevent synthesis of cell walls so as to play an antibacterial role, and a plurality of constructed living body models show that the compound can effectively reduce the content of bacteria in a body and promote wound repair and has in-vivo medication safety. The research result shows that the GaB can be used as a safe and effective novel pilot natural active small molecule for resisting infection of multiple drug-resistant bacteria.

The application discloses a D-type amino acid-based antibacterial peptide and application thereof, and has the amino acid sequence of w-r-r-w-r-r-w-w-r-k-r (dTrp-dArg-dArg-dTrp-dArg-dArg-dTrp-dTrp-dArg-dLys-dArg). The antibacterial peptide can be synthesized by Fmoc solid-phase chemical synthesis, has low synthesis difficulty, and has good in-vivo antibacterial activity. The antibacterial peptide has broad-spectrum killing activity on carbapenem-resistant pseudomonas aeruginosa, pseudomonas aeruginosa, klebsiella pneumoniae, escherichia coli, methicillin-resistant staphylococcus aureus and staphylococcus aureus, has low hemolytic toxicity, can reach more than half of the cell survival rate at a medium or low concentration, has almost no toxic effect on cells, has good stability, has strong operability, and is low in cost.